Technical brief

HPE Cray

The role of modeling and simulation in life sciences

Executive summary

Modeling and simulation technologies are now essential tools in life sciences, fundamentally reshaping drug discovery, clinical trials, and patient care. Through virtual testing environments, these technologies enable researchers and clinicians to optimize processes, make accurate predictions, and develop personalized treatment strategies. This not only enhances patient care but also supports cost management in a complex healthcare landscape.

Introduction

Fueled by advances in high performance computing (HPC), artificial intelligence (AI), and cloud technology, modeling and simulation are deeply embedded in life sciences workflows. These tools enable major pharmaceutical companies to enhance productivity, minimize risk, and bring treatments to market faster than ever before, providing a competitive advantage in drug development and healthcare innovation.

1. Modeling and simulation in research and development (R&D)

Modeling and simulation empower researchers to visualize complex molecular interactions and predict therapeutic effectiveness, enabling the identification of promising drug candidates more efficiently.

- **Molecular dynamics for protein modeling:** Molecular dynamics (MD) simulations allow researchers to analyze how drugs interact with biological targets such as proteins. During the COVID-19 pandemic, MD simulations helped researchers identify potential binding sites, rapidly narrowing down therapeutic options. This technology continues to play a crucial role in structural biology, aiding in the design of molecules that interact precisely with target proteins.
- **In silico screening in oncology:** Virtual screening in cancer research allows scientists to evaluate thousands of compounds to identify those with the highest potential efficacy. This approach reduces the need for early-stage lab testing and provides a more sustainable method for screening therapeutic candidates. In silico screening techniques have become instrumental in oncology, where time to market is crucial for effective treatment options.
- **AI-driven drug discovery platforms:** Leveraging machine learning, these platforms predict which compounds will successfully interact with target proteins, helping researchers prioritize candidates with the highest likelihood of success. AI-driven drug discovery platforms have led to breakthroughs in various therapeutic areas, offering a more precise way to streamline early drug development.

2. Applications in clinical trials

Modeling and simulation are also reshaping clinical trials, helping to reduce costs, mitigate risks, and improve patient outcomes by predicting biological responses across diverse populations.

- **Virtual patient populations for physiologically-based pharmacokinetic (PBPK) modeling:** PBPK modeling allows researchers to simulate how drugs interact with different population groups, such as children and older patients. This approach reduces the need for large trial populations and offers insights into the efficacy and safety of treatments across diverse demographics.
- **Simulation-enabled real-world evidence (RWE):** RWE models predict how a drug might perform in real-world settings, complementing traditional clinical trial data. This method enhances decision-making by integrating real-world scenarios, thereby supporting more reliable trial outcomes and post-market assessments.

3. Patient-centric applications

Modeling and simulation enable more personalized approaches to patient care, including precision dosing, chronic disease management, and presurgical planning.

- **Predictive modeling in chronic disease management:** Predictive models help clinicians monitor disease progression and determine optimal intervention strategies. For instance, cardiac simulation projects such as the Living Heart Project provide insights into heart disease, enabling clinicians to tailor treatments for individual patients based on their unique cardiac profiles.
- **Personalized dosing in oncology:** By simulating patient-specific pharmacokinetics, healthcare providers can adjust chemotherapy doses according to individual tolerance levels, reducing toxic side effects while maximizing therapeutic efficacy. This approach enhances patient outcomes, particularly in cancer treatments where personalized care is vital.
- **Presurgical planning:** Virtual anatomical models assist surgeons in planning complex procedures, minimizing risks by simulating potential complications. By analyzing a patient's unique anatomy beforehand, clinicians can better prepare for the surgery, resulting in improved precision and patient outcomes.

4. Technological advances enabling modeling and simulation

Recent advances in AI, HPC, and cloud platforms have made it possible to conduct complex simulations on a larger scale, improving both cost efficiency and predictive accuracy.

- **AI for protein structure prediction:** AI-driven platforms such as AlphaFold are transforming the field of protein modeling, providing accurate predictions of protein structures. This capability accelerates research across various life sciences fields, enabling scientists to target diseases more effectively.
- **Cloud-based HPC for scalable simulations:** Platforms such as HPE GreenLake enable scalable simulations, reducing infrastructure costs by an average of 40%. Hewlett Packard Enterprise reports that cloud-based HPC has allowed life sciences firms to conduct more frequent, complex simulations, thus enhancing project flexibility.[1]
- **GPU-accelerated molecular dynamics:** GPU advancements have significantly increased the speed of MD simulations, enabling researchers to conduct extensive studies in a fraction of the time. This acceleration supports rapid iteration and testing in the development of new therapies.

[1] Based on HPE internal study, 2024

5. Challenges and future directions

Despite their advantages, modeling and simulation face challenges in terms of validation, data requirements, and regulatory compliance. However, emerging solutions promise to address these barriers.

- **Real-time simulation in clinical care:** Real-time simulation, driven by patient monitoring data, holds potential for critical care applications. By continuously updating based on real-world patient data, simulations could support immediate decision-making in complex clinical scenarios.
- **AI-augmented modeling for rare diseases:** AI-enhanced models offer improved predictive power for rare diseases, an area traditionally limited by scarce data. These models facilitate research on rare conditions by synthesizing limited information into actionable insights, ultimately guiding the development of targeted therapies.

Conclusion

Modeling and simulation technologies are revolutionizing life sciences, enhancing efficiency in drug discovery, clinical trials, and personalized care. As HPC and AI technology continue to advance, these tools will further drive innovation, providing life sciences professionals with the resources to improve patient outcomes and accelerate research breakthroughs.

Learn more at

HPE.com/supercomputing

Visit **HPE GreenLake**

Chat now (sales)

Hewlett Packard Enterprise

a00143500ENW